Alto Neuroscience (ANRO) Total Non-Current Liabilities (2023 - 2024)
Alto Neuroscience (ANRO) reported Total Non-Current Liabilities of $26.1 million for Q4 2024, up 68.59% on a YoY basis from $15.5 million in Q1 2024, and down 1.78% sequentially from $26.6 million in Q3 2024.
Alto Neuroscience (ANRO) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Alto Neuroscience (ANRO) has 2 years of Total Non-Current Liabilities data on file, last reported at $26.1 million in Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities rose 68.59% year-over-year to $26.1 million; the trailing twelve-month figure through Dec 2024 stood at $26.1 million (up 68.59% YoY), and the FY2024 full-year result was $26.1 million, up 68.59% from the prior year.
- Total Non-Current Liabilities declined to $26.1 million in Q4 2024, from $26.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $26.6 million in Q3 2024 to a low of -$1.7 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Alto Neuroscience | 881.86 Mn | 881.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 26.08 Mn |
| Sep 30, 2024 | 26.56 Mn |
| Jun 30, 2024 | 17.58 Mn |
| Mar 31, 2024 | 16.82 Mn |
| Dec 31, 2023 | 15.47 Mn |
| Sep 30, 2023 | -1.40 Mn |
| Jun 30, 2023 | -1.60 Mn |
| Mar 31, 2023 | -1.70 Mn |